In this article, with a focus on lipid-based formulations, Stephen Tindal, Director, Scientific Affairs, Catalent Pharma Solutions, provides insights into Catalent’s strategies for oral formulation selection which can lower attrition rates, and therefore development costs and time to market.

Link to ONdrugDelivery Magazine